Relay Therapeutics (RLAY) and The Competition Head to Head Survey

Relay Therapeutics (NASDAQ:RLAY – Get Free Report) is one of 844 public companies in the “Biotechnology” industry, but how does it contrast to its competitors? We will compare Relay Therapeutics to similar companies based on the strength of its analyst recommendations, valuation, profitability, risk, earnings, dividends and institutional ownership.

Insider and Institutional Ownership

97.0% of Relay Therapeutics shares are owned by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are owned by institutional investors. 5.0% of Relay Therapeutics shares are owned by insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Risk and Volatility

Relay Therapeutics has a beta of 1.74, indicating that its stock price is 74% more volatile than the S&P 500. Comparatively, Relay Therapeutics’ competitors have a beta of 1.15, indicating that their average stock price is 15% more volatile than the S&P 500.

Profitability

This table compares Relay Therapeutics and its competitors’ net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent recommendations for Relay Therapeutics and its competitors, as reported by MarketBeat.

Relay Therapeutics presently has a consensus price target of $25.92, suggesting a potential upside of 39.34%. As a group, “Biotechnology” companies have a potential upside of 102.70%. Given Relay Therapeutics’ competitors higher possible upside, analysts plainly believe Relay Therapeutics has less favorable growth aspects than its competitors.

Valuation & Earnings

This table compares Relay Therapeutics and its competitors top-line revenue, earnings per share and valuation.

Relay Therapeutics’ competitors have higher revenue and earnings than Relay Therapeutics. Relay Therapeutics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Summary

Relay Therapeutics beats its competitors on 8 of the 13 factors compared.

About Relay Therapeutics

(Get Free Report)

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company’s lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.